Updated:
ORI Capital
ORI Capital is a venture capital firm that invests in healthcare technology companies worldwide. It has made 10 investments, including a Series E investment in...
ORI Capital
ORI Capital is a venture capital firm that invests in healthcare technology companies worldwide. It has made 10 investments, including a Series E investment in CG Oncology on November 15, 2022. The firm has facilitated 4 portfolio exits, with CG Oncology being its most recent exit on January 25, 2024.
General information
Firm type
Venture Capital
Year founded
2015
AUM
Undisclosed
Location
Region
Asia
Country
Hong Kong
City
Hong Kong
Corporate office
Hong Kong, Hong Kong
Principals
Simone Song
Founder & Senior Partner
Sector focus
Frequently asked questions
Who runs investment decisions at ORI Capital?
Founder and Senior Partner Simone Song leads the firm she established in 2015. The 'Our Team' page on ORI Capital's website lists additional Partners and an Operating Partner, but investment authority appears concentrated around Song and the senior partnership group.
How does ORI Capital source proprietary deal flow?
ORI Capital employs a dedicated data science team — including a Vice President, data engineers, and analysts — to screen scientific literature, patent databases, and clinical-trial registries using proprietary machine-learning tools. This in-house capability functions as an AI-driven origination engine, designed to identify therapeutic and diagnostic assets before they appear on conventional VC radars.
What therapeutic areas does ORI Capital focus on?
The firm targets diagnostics, drug delivery, and therapeutics across the three disease categories with the highest global mortality rates: cancer, cardiovascular disease, and neurodegenerative conditions. Its website does not indicate investment in platform biotech tools or non-therapeutic health IT.
Does ORI Capital invest only in early-stage companies?
ORI Capital describes itself as an early-stage venture firm and its portfolio language is consistent with seed-through-growth biotech investing. The firm has been involved with portfolio companies from initial development through exit, as demonstrated by Semma Therapeutics, which was acquired by Vertex.
What is a known exit from ORI Capital's portfolio?
Semma Therapeutics, a cell-therapy company developing a potential cure for type 1 diabetes, was acquired by Vertex Pharmaceuticals. ORI Capital's website highlights this as an 'Exited' and 'Listed' portfolio company, indicating the firm held the position into a public or acquisition outcome.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: